medigraphic.com
Coordinación General de Investigación de la Facultad de Salud Pública y Nutrición y la Dirección General de Sistemas e Informática de la Universidad Autónoma de Nuevo León

2004, Número 2

<< Anterior Siguiente >>

Rev Salud Publica Nutr 2004; 5 (2)


Opioides sintéticos no peptídicos con propiedades Inmunomoduladoras y antitumorales

Caballero-Hernández D, Tamez-Guerra R, Rodríguez-Padilla C, Tamez-Guerra P, Weber RJ, Gómez FR

Idioma: Español
Referencias bibliográficas: 45
Paginas:
Archivo PDF: 92.46 Kb.


RESUMEN

El diseño y síntesis de opioides no peptídicos con un perfil farmacológico especifico representa un prometedor campo de estudio, así como una fuente de nuevos compuestos con potencial aplicación terapéutica. En este trabajo hemos evaluado una serie de opioides sintéticos no peptídicos por sus propiedades inmunoreguladoras y antitumorales. Los resultados de este estudio apoyan la noción según la cual los opioides sintéticos, en la misma forma que los naturales, poseen propiedades bioreguladoras de importancia. Mas aun, las observaciones obtenidas con el agonista opioide SNC 80, sugieren para este compuesto un gran potencial clínico como analgésico no inmunosupresor, y/o agente antitumoral.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sharp, B.M., W.F. Keane, H.J. Suh, G. Gekker, D. Tsukayama and P.K. Peterson. 1985. Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. Endocrinology Vol. 117: 793-795.

  2. Shavit Y., G.W. Terman, F.A. Martin, J.W. Lewis, J.C. Liebeskind and R.P. Gale, R.P. 1985. Stress, opioid peptides, the immune system, and cancer. J. Immunol. Vol. 135: 2.

  3. Weber, R.J. and A. Pert. 1989. The periaqueductal gray matter mediates opiate-induced immunosuppression. Science Vol. 245: 188-190.

  4. Roy, S. and H.H. Loh. 1996. Effects of opioids on the immune system. Neurochem. Res. Vol. 21: 1375.

  5. Guan, L., R. Townsend, T.K. Eisenstein, M.W. Adler and T.J. Rogers. 1995. The cellular basis for opioid-induced immunosuppression. Adv. Exp. Med. Biol. Vol. 373: 57-64.

  6. Tubaro, E., G. Borelli, C. Croce, G. Cavallo and C. Santiangeli. 1983. Effect of morphine on resistance to infection. J. Infect. Dis. Vol. 148: 656-666.

  7. Watson, R.R., R.H. Prabhala, H.R. Darban, M.D. Yahya and T.L. Smith. 1988. Changes in lymphocyte and macrophage subsets due to morphine and ethanol treatment during a retrovirus infection causing murine AIDS. Life Sci Vol. 43: v-xi.

  8. Yeager, M.P. and T.A. Colacchio. 1991. Effect of morphine on growth of metastatic colon cancer in vivo. Arch. Surg. Vol. 126: 454-456.

  9. Hambrook, J.M., B.A. Morgan, M.J. Rance and C.F. Smith. 1976. Mode of deactivation of the enkephalins by rat and human plasma and rat brain homogenates. Nature. Vol. 262 No. 5571: 782-3.

  10. Nowak, J.E., R. Gomez-Flores, S.N. Calderon, K.C. Rice and R.J. Weber 1998. Rat natural killer cell, T cell and macrophage functions after intracerebroventricular injection of SNC 80. J. Pharmacol. Exp. Ther. Vol. 286: 931-937.

  11. Gomez-Flores, R., K.C. Rice, X. Zhang and R.J. Weber. 2001. Increased tumor necrosis factor-alpha and nitric oxide production by rat macrophages following in vitro stimulation and intravenous administration of the delta-opioid agonist SNC80. Life Sci. Vol. 68 No. 24: 2675-84.

  12. Riley, M.E., S. Ananthan and R.J. Weber. 1998. Novel Non-peptidic opioid compounds with immunopotentiating effects. Adv. Exp. Med. Biol. Vol. 437: 183-187.

  13. Gómez-Flores, R. and R.J. Weber. 1999. Inhibition of interleukin-2 production and downregulation of IL-2 and transferrin receptors on rat splenic lymphocytes following PAG morphine administration: a role in natural killer and T cell supresion. J. Interferon Cytokine Res. Vol. 19: 625-30.

  14. Gómez-Flores, R. and R.J. Weber. 2000. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray Immunopharmacology Vol. 48 No. 2: 145-56.

  15. Franco-Molina, M., R. Gomez-Flores, P. Tamez-Guerra, R. Tamez-Guerra, L. Castillo-Leon and C. Rodríguez-Padilla. 2003. In vitro Immunopotentiating Properties and Tumor Cell Toxicity Induced by Lophophora williamsii (Peyote) Cactus Methanolic Extract. Phytother. Res. Vol. 17 No. 9: 1076-81.

  16. Gomez-Flores, R. et. al., Op.cit.

  17. Gómez-Flores, R. and R.J. Weber. 2000, Op.cit.

  18. Franco-Molina, M., et. al., Op.cit.

  19. Idem.

  20. Carpenter, G.W., L. Breeden and D.J. Carr. 1995. Acute exposure to morphine suppresses cytotoxic Tlymphocyte activity. Int. J. Immunopharmacol. Vol. 17 No. 12: 1001-6.

  21. Zagon, I.S. and P.J. McLaughlin. 2003. Opioids and the apoptotic pathway in human cancer cells. Neuropeptides Vol. 37 No. 2: 79-88.

  22. Kawase, M., H. Sakagami, K. Furuya, H. Kikuchi, H. Nishikawa, N. Motohashi, Y. Morimoto, A. Varga and J. Molnar. 2002. Cell death-inducing activity of opiates in human oral tumor cell lines. Anticancer Res. Vol. 22 No. 1A: 211-4.

  23. Bonn, D. 2002. Morphine stimulates tumour growth. Lancet Oncol. Vol. 3 No. 9: 520.

  24. Kajdaniuk, D., B. Marek, B. Buntner and K. Zwirska-Korczala. 2000. Do enkephalins and other endogenous opioids participate in regulation of cancer growth?. Postepy. Hig. Med. Dosw. Vol. 54 No. 5: 597-608.

  25. Dickenson, A.H. 1997. Plasticity: implication for opioid and other pharmacological interventions in specific pain states. Behav. Brain Sci. Vol. 20:392-403.

  26. Nowak, J.E. et al., Op. cit.

  27. Gómez-Flores, R. and R.J. Weber. 1999, Op. cit.

  28. Gómez-Flores, R. and R.J. Weber. 2000, Op.cit.

  29. McCarthy, L., M. Wetze, J.K. Sliker, T.K. Eisenstein and T.J. Rogers. 2001. Opioid, opioids receptors and the immune response. Drug Alcohol Depend. Vol. 62 No. 2: 111-123.

  30. Carr, D.J., R.T. Radulescu, B.R. deCosta, K.C. Rice and J.E. Blalock. 1990. Differential effect of opioids on immunoglobulin production by lymphocytes isolated from Peyer´s patches and spleen. Life Sci. Vol. 47 No. 12: 1059-69.

  31. Dantzer, R. and K.W. Kelley. 1989. Stress and immunity: an integrated view of relationships between the brain and the immune system. Life Sci. Vol. 1995: 2008

  32. Maneckjee, R., R. Biswas and B.K. Vonderhaar. 1990. Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res. Vol. 50: 2234-2238

  33. Maneckjee, R. and J.D. Minna. 1990. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc. Natl. Acad. Sci. U.S.A. Vol. 87: 3294-3300.

  34. Panagiotou, S., E. Bakogeorgou, E. Papakonstanti, A. Hatzoglou, F. Wallet, C. Dussert, C. Stournaras, P.M. Martin and E. 1999. Opioid agonists modify breast cancer cell proliferation by blocking cells to the G2/M phase of the cycle: involvement of cytoskeletal elements. J. Cell. Biochem. Vol. 73 No. 2: 204-11.

  35. Calderon, S.N., R.B. Rothman, F. Porreca, J.L. Flippen-Anderson, R.W. McNutt, H. Xu, L.E. Smith, E.J. Bilsky, P. Davis and K.C. Rice. 1994. Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+) (+)-4-((alpha R)9-alpha-((2S, 5R)-4-allyl-2, 5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N, N-diethyl-benzamide (SNC80): A highly selective, nonpeptide d opioid receptor. J. Med. Chem. Vol. 37: 2125-2128.

  36. Bilsky, E.J., S.N. Calderon T. Wang, R.N. Bernstein, P. Davis, V.J. Hruby, R.W. McNutt, R.B. Rothman, K. Rice and F. Porreca. 1995. SNC80, a selective, nonpeptidic and systemically active opioid delta agonist. J. Pharmacol. Exp. Ther. Vol. 273: 359-66.

  37. Negus, S.S., M.B. Gatch, N.K. Mello, X. Zhang and K. Rice. 1998. Behavioral effects of tha deltaselective opioid agonist SNC80 and related compounds in rhesus monkey. J. Pharm. Exp. Ther. Vol. 286: 362-375.

  38. Nowak, J.E. et al., Op. cit.

  39. Gomez-Flores, R. et. al., Op.cit

  40. Weber, R.J. and A. Pert, Op.cit.

  41. Gómez-Flores, R. and R.J. Weber. 1999, Op. cit.

  42. Gómez-Flores, R. and R.J. Weber. 2000, Op.cit.

  43. Hohenwarter, O., K. Strutzenberger, H. Katinger, A. Liepins and J.W. Nowicky. 1992. Selective inhibition of in vitro cell growth by the anti-tumour drug ukrain. Drugs Exp. Clin. Res. Vol. 18: Suppl (1-4).

  44. Zhang, X.D, T. Nguyen, W.D. Thomas, J.E. Sanders and P. Hersey. 2000. Mechanisms of resistance of normal cells to TRAIL induced apptosis vary between different cell types. FEBS Lett. Vol. 482: 193-199.

  45. Durig J., N.G. Testa, B.I. Lord, C. Kasper, J. Chang, N. Telrford, T.M. Dexter and C.M. Heyworth. 1999. Characterization of the differential response of normal and CML haemopoietic progenitor cells to macrophage inflammatory protein-1alpha. Leukemia Vol. 13: 2012-2022




2020     |     www.medigraphic.com